Results 61 to 70 of about 11,033 (240)

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

Pharmaceutics, 2021
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor.
Aksana Jones, Orit Cohen-Barak, Andrijana Radivojevic, Jill Fiedler-Kelly   +3 more
doaj   +1 more source

Evidence-based drug treatment for special patient populations through model-based approaches [PDF]

, 2017
The majority of marketed drugs remain understudied in some patient populations such as pregnant women, paediatrics, the obese, the critically-ill, and the elderly.
Allegaert, K.M. (Karel), Anker, J.N. (John) van den, Hasselt, J.G.C. (Johan) van, Knibbe, C.A.J. (Catherijne), Krekels, E.H.J. (Elke), Tibboel, D. (Dick)   +5 more
core   +3 more sources

Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children

British Journal of Clinical Pharmacology, EarlyView.
This systematic review identified 112 population pharmacokinetic models of vancomycin in neonates and children. To support rational model selection for model‐informed precision, we developed and applied expert‐driven, transparent criteria that integrate both methodological rigour and clinical relevance.
Zoë Vander Elst, Pieter‐Jan Spiessens, Dorian Vanneste, Nada Dia, Matthias Gijsen, Isabel Spriet, Karel Allegaert, Erwin Dreesen, Anne Smits   +8 more
wiley   +1 more source

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

CPT: Pharmacometrics & Systems Pharmacology, 2020
Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites.
Emmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda Karen Sykes, Maria M. Posada, Jan‐Stefan van derWalt, P. Kellie Turner   +5 more
doaj   +1 more source

A perspective on the current use of the phase distribution model for predicting milk‐to‐plasma drug concentration ratio

CPT: Pharmacometrics & Systems Pharmacology, 2022
The phase distribution model, proposed by Atkinson and Begg in 1990, has been widely used for predicting breastmilk‐to‐plasma drug concentration ratio. However, misrepresentations of the equations have been noted in recent publications.
Mian Zhang, Caroline Sychterz, Ming Chang, Lu Huang, Brian J. Schmidt, Lu Gaohua   +5 more
doaj   +1 more source

The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia

Pharmaceutics, 2021
The treatment of respiratory tract infections is threatened by the emergence of bacterial resistance. Immunomodulatory drugs, which enhance airway innate immune defenses, may improve therapeutic outcome.
Robin Michelet, Moreno Ursino, Sandrine Boulet, Sebastian Franck, Fiordiligie Casilag, Mara Baldry, Jens Rolff, Madelé van Dyk, Sebastian G. Wicha, Jean-Claude Sirard, Emmanuelle Comets, Sarah Zohar, Charlotte Kloft   +12 more
doaj   +1 more source

The International Society of Pharmacometrics [PDF]

Journal of Pharmacokinetics and Pharmacodynamics, 2013
In 2011, the American Society of Pharmacometrics (ASoP) was founded and over 600 members worldwide joined ASoP within 6 months. In 2012, ASoP evolved to the International Society of Pharmacometrics (ISoP) to reflect the increasing number of international members.
Marc Pfister, Donald E. Mager, Nicholas H. G. Holford, Brian Corrigan, Stacey Tannenbaum, Rene Bruno, Liping Zhang, Yaning Wang, David Z. D’Argenio   +8 more
openaire   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Drugs in R&D
Background and Objective Paroxysmal nocturnal hemoglobinuria is a rare blood disorder characterized by life-threatening hemolysis and thrombosis. Complement C5 inhibitor therapy improves symptoms and life prognosis; however, it can result in insufficient
Ryan L. Crass, Brandon Smith, Sven Adriaens, Sunny Chapel, Grant Langdon   +4 more
doaj   +1 more source